Human herpesvirus-6, -7, and Epstein-Barr virus reactivation in pityriasis rosea during COVID-19.
作者信息
Drago Francesco, Ciccarese Giulia, Rebora Alfredo, Parodi Aurora
机构信息
Dermatology Unit, Ospedale Policlinico San Martino, Genoa, Italy.
Section of Dermatology, Di. S. Sal, University of Genoa, Genoa, Italy.
出版信息
J Med Virol. 2021 Apr;93(4):1850-1851. doi: 10.1002/jmv.26549. Epub 2020 Oct 7.
Abstract
摘要
相似文献
1
Human herpesvirus-6, -7, and Epstein-Barr virus reactivation in pityriasis rosea during COVID-19.
J Med Virol. 2021 Apr;93(4):1850-1851. doi: 10.1002/jmv.26549. Epub 2020 Oct 7.
2
HHV 6-7 reactivation causing Pityriasis Rosea and labyrinthitis: A case report.
Am J Emerg Med. 2020 Sep;38(9):1969.e1-1969.e3. doi: 10.1016/j.ajem.2020.05.005. Epub 2020 May 16.
3
[Pityriasis rosea. Reactivation of human Herpesvirus 6 and 7 infection?].
Hautarzt. 2003 Jan;54(1):78-9. doi: 10.1007/s00105-002-0474-1. Epub 2002 Dec 21.
4
Concurrent pityriasis rosea and Bell's palsy.
BMJ Case Rep. 2017 Jan 23;2017:bcr2016218069. doi: 10.1136/bcr-2016-218069.
5
Pityriasis Rosea in Children: Clinical Features and Laboratory Investigations.
Dermatology. 2015;231(1):9-14. doi: 10.1159/000381285. Epub 2015 May 12.
6
Pityriasis rosea and herpesviruses: facts and controversies.
Clin Dermatol. 2010 Sep-Oct;28(5):497-501. doi: 10.1016/j.clindermatol.2010.03.005.
7
Pityriasis Rosea after COVID-19 Infection.
Acta Dermatovenerol Croat. 2022 Dec;30(4):265-266.
8
[Chronic fatigue syndrome].
Nihon Rinsho. 2006 Mar;64 Suppl 3:490-5.
9
The role of human herpesvirus 6, human herpesvirus 7, Epstein-Barr virus and cytomegalovirus in the aetiology of pityriasis rosea.
J Eur Acad Dermatol Venereol. 2009 Jan;23(1):16-21. doi: 10.1111/j.1468-3083.2008.02939.x. Epub 2008 Aug 18.
10
Pityriasis rosea is associated with systemic active infection with both human herpesvirus-7 and human herpesvirus-6.
J Invest Dermatol. 2002 Oct;119(4):793-7. doi: 10.1046/j.1523-1747.2002.00200.x.
引用本文的文献
1
Acute COVID-19 and LongCOVID syndrome - molecular implications for therapeutic strategies - review.
Front Immunol. 2025 Apr 17;16:1582783. doi: 10.3389/fimmu.2025.1582783. eCollection 2025.
2
Potential Biomarkers for Predicting the Risk of Developing Into Long COVID After COVID-19 Infection.
Immun Inflamm Dis. 2025 Jan;13(1):e70137. doi: 10.1002/iid3.70137.
3
Understanding autoimmune response after SARS-CoV-2 infection and the pathogenesis/mechanisms of long COVID.
Med Rev (2021). 2024 May 27;4(5):367-383. doi: 10.1515/mr-2024-0013. eCollection 2024 Oct.
4
Association between Pityriasis Rosea (PR) and HHV-6/HHV-7 Infection: Importance of Sample Selection and Diagnostic Techniques.
Diagnostics (Basel). 2024 Apr 18;14(8):843. doi: 10.3390/diagnostics14080843.
5
Pityriasis following COVID-19 vaccinations: a systematic review.
Dermatol Reports. 2023 Aug 9;16(1):9742. doi: 10.4081/dr.2023.9742. eCollection 2024 Mar 12.
6
Precision nutrition to reset virus-induced human metabolic reprogramming and dysregulation (HMRD) in long-COVID.
NPJ Sci Food. 2024 Mar 30;8(1):19. doi: 10.1038/s41538-024-00261-2.
7
Effect of monovalent COVID-19 vaccines on viral interference between SARS-CoV-2 and several DNA viruses in patients with long-COVID syndrome.
NPJ Vaccines. 2023 Sep 29;8(1):145. doi: 10.1038/s41541-023-00739-2.
8
Shared Pathogenicity Features and Sequences between EBV, SARS-CoV-2, and HLA Class I Molecule-binding Motifs with a Potential Role in Autoimmunity.
Clin Rev Allergy Immunol. 2023 Aug;65(2):206-230. doi: 10.1007/s12016-023-08962-4. Epub 2023 Jul 28.
9
A Review of Pityriasis Rosea in Relation to SARS-CoV-2/COVID-19 Infection and Vaccination.
Cureus. 2023 May 9;15(5):e38772. doi: 10.7759/cureus.38772. eCollection 2023 May.
10
Viral persistence, reactivation, and mechanisms of long COVID.
Elife. 2023 May 4;12:e86015. doi: 10.7554/eLife.86015.
本文引用的文献
1
Pityriasis rosea Gibert type rash in an asymptomatic patient that tested positive for COVID-19.
Med Clin (Engl Ed). 2020 Sep 25;155(6):273. doi: 10.1016/j.medcle.2020.05.017. Epub 2020 Sep 4.
2
SARS-CoV-2 as possible inducer of viral reactivations.
Dermatol Ther. 2020 Nov;33(6):e13878. doi: 10.1111/dth.13878. Epub 2020 Jul 6.
3
Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents?
J Microbiol Immunol Infect. 2020 Aug;53(4):505-512. doi: 10.1016/j.jmii.2020.05.013. Epub 2020 May 23.
4
Editorial - COVID-19, more than a viral pneumonia.
Eur Rev Med Pharmacol Sci. 2020 May;24(9):5183-5185. doi: 10.26355/eurrev_202005_21216.
5
Pityriasis rosea as a cutaneous manifestation of COVID-19 infection.
J Eur Acad Dermatol Venereol. 2020 Sep;34(9):e436-e437. doi: 10.1111/jdv.16579. Epub 2020 Jun 11.
6
Coinfection in SARS-CoV-2 infected patients: Where are influenza virus and rhinovirus/enterovirus?
J Med Virol. 2020 Oct;92(10):1699-1700. doi: 10.1002/jmv.25953. Epub 2020 Jul 17.
7
Digitate Papulosquamous Eruption Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
JAMA Dermatol. 2020 Jul 1;156(7):819-820. doi: 10.1001/jamadermatol.2020.1704.
8
Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases.
Br J Dermatol. 2020 Jul;183(1):71-77. doi: 10.1111/bjd.19163. Epub 2020 Jun 10.
9
Cutaneous Clinico-Pathological Findings in three COVID-19-Positive Patients Observed in the Metropolitan Area of Milan, Italy.
Acta Derm Venereol. 2020 Apr 23;100(8):adv00124. doi: 10.2340/00015555-3490.
10
Viral reactivation and skin eruptions.
Dermatology. 2003;207(1):1-2. doi: 10.1159/000070931.
Zotero 插件